title: [Thrombolysis in cerebral ischemia. An overview].
abstract: Thrombolytic therapy for acute ischemic stroke within the 3-h time window has been approved. In the US, where FDA approval has existed for about 4 years, less than 2% of stroke patients presently receive thrombolytic therapy. This review illustrates all completed trials of intravenous and intra-arterial thrombolytic therapy for carotid artery and vertebrobasilar artery stroke and includes recommendations for therapy, diagnostic procedures and their effect on patient selection, meta-analyses, phase IV trials, and cost efficacy analyses.
authors.affiliation: Neurologische Klinik des Universitätsklinikum Heidelberg, im Neuenheimer Feld 400, Kopfklinik, 69120 Heidelberg. Peter_Schellinger@med.uni-heidelberg.de
authors.forename: P D
authors.initials: PD
authors.lastname: Schellinger
authors.forename: J
authors.initials: J
authors.lastname: Fiebach
authors.forename: P A
authors.initials: PA
authors.lastname: Ringleb
authors.forename: O
authors.initials: O
authors.lastname: Jansen
authors.forename: W
authors.initials: W
authors.lastname: Hacke
mesh_terms: D002544:Cerebral Infarction / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
vernacular_title: Thrombolyse bei zerebraler Ischämie. Eine Ubersicht.